Eyenuk

Eyenuk is a medtech company that develops an artificial intelligence screening tool for risk assessment and disease surveillance. The company's first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for the autonomous detection of diabetic retinopathy. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life-and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease.

The company was founded in 2010 and is based in Los Angeles, California.

Eyenuk headquartered in United States, North America, operates in the Artificial Intelligence (AI), Health Care, Medical Device, Diabetes, Health Diagnostics sector. The company focuses on Artificial Intelligence (AI) and has secured $11.4B in funding across 240 round(s). With a team of 11-50 employees, Eyenuk is actively contributing to advancements in Artificial Intelligence (AI). Their latest funding round, Seed Round - Eyenuk, raised $1.5M. Discover more about their projects, partnerships, and impact on our platform.